Bio-Techne and USP Join Forces for Antibody Development Innovation
Bio-Techne Collaborates with USP for Enhanced Therapeutics
Bio-Techne Corporation (NASDAQ: TECH) is charting a new course in the biopharmaceutical sector with its latest distribution agreement with the U.S. Pharmacopeia (USP). This partnership allows Bio-Techne to market USP's monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions like the Maurice system. This collaboration aims to bolster monoclonal antibody and gene therapy development globally.
The Growing Importance of mAb Quality
In recent years, over 160 antibody therapies targeting nearly 100 distinct diseases have received global approval. Maintaining high-quality standards for mAbs is crucial for their therapeutic efficacy. As patent protections for existing mAbs expire, biosimilar alternatives are entering the market, intensifying the necessity for manufacturers to meticulously test critical quality attributes throughout the development and production processes. This ensures the safety and effectiveness of their products.
Gene Therapy: Challenges and Opportunities
Gene therapy is rapidly becoming one of the most promising areas of innovation within the biotech industry, utilizing recombinant AAV to deliver gene alterations directly into cells. This sector faces its own set of challenges, including low production yields, scalability issues, high costs, and complex analytical requirements. USP's reference standards provide essential benchmarks that simplify these hurdles, ensuring compliance and reliability during analytical testing.
Benefits of the Collaboration
The integration of USP's mAb and AAV reference standards with Bio-Techne's leading-edge analytical instruments, including the MauriceFlex™ system, is a game-changer for therapy developers. This collaboration facilitates reliable and efficient characterization, enhancing accuracy in evaluating purity, charge, size, and identity—all crucial factors in the development process of complex biologics.
Statements from Key Leaders
Will Geist, President of Bio-Techne's Protein Sciences Segment, expressed excitement about this partnership, stating, "We are thrilled about our work with USP, marking a pivotal moment in our mission to provide advanced tools and solutions for the scientific community. This collaboration highlights our commitment to fostering innovation in biotherapeutic development and ensuring utmost quality and safety standards for patient healthcare."
Fouad Atouf, Ph.D., Senior Vice President of Global Biologics at USP, also shared his enthusiasm: "We are excited to collaborate with Bio-Techne as an authorized distributor, which will help us enhance access to our solutions for the scientific community. This partnership ensures that high-quality therapeutic products reach the patients who need them."
Focus on Quality Challenges
Addressing quality challenges is a vital part of guaranteeing the safety and efficacy of biotherapeutics. Bio-Techne and USP both bring extensive experience in developing solutions for mAb and are now applying that knowledge to overcome analytical challenges faced by AAV-based gene therapies. By allowing the purchase of USP reference standards through Bio-Techne, the process of method development is streamlined. Customers can effectively assess system suitability and critical criteria for charge and size-based analytical assays using the Maurice system.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is known for providing innovative life science tools and bioactive reagents to the research and clinical diagnostic arenas. Its extensive product offerings enable scientists to explore biological processes and the progression of diseases meticulously. Moreover, Bio-Techne's solutions assist in drug discovery while ensuring precise clinical testing and diagnoses. The company, with a product portfolio that includes hundreds of thousands of items, generated approximately $1.2 billion in net sales in the last fiscal year and has a workforce of about 3,100 employees worldwide.
For more engaging insights into Bio-Techne, explore their brands and offerings via their official website or through their active social media channels.
Frequently Asked Questions
What is the purpose of the Bio-Techne and USP collaboration?
The collaboration aims to enhance the development process of monoclonal antibodies and gene therapies by using USP's quality reference standards.
How many antibody therapies have been approved worldwide?
Over 160 antibody therapies targeting nearly 100 different diseases have received global approval.
What issues does gene therapy face?
Challenges include low yields, scalability, high costs, and complex analytics that make development and commercialization difficult.
What advantages do USP standards provide?
They offer well-characterized benchmarks for testing, ensuring accuracy and regulatory compliance during product development.
What is the significance of maintaining antibody quality?
Consistency in mAb quality is essential for ensuring the efficacy and safety of therapeutic treatments, especially as biosimilars emerge.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
